Cargando…
Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
PURPOSE: The purpose of this study was to evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolizat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961082/ https://www.ncbi.nlm.nih.gov/pubmed/33738247 http://dx.doi.org/10.3389/fonc.2021.582544 |
_version_ | 1783665180479062016 |
---|---|
author | Ren, Yanqiao Dong, Xiangjun Chen, Lei Sun, Tao Alwalid, Osamah Kan, Xuefeng Su, Yangbo Xiong, Bin Liang, Huimin Zheng, Chuansheng Han, Ping |
author_facet | Ren, Yanqiao Dong, Xiangjun Chen, Lei Sun, Tao Alwalid, Osamah Kan, Xuefeng Su, Yangbo Xiong, Bin Liang, Huimin Zheng, Chuansheng Han, Ping |
author_sort | Ren, Yanqiao |
collection | PubMed |
description | PURPOSE: The purpose of this study was to evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolization (TACE). METHODS: This retrospective study analyzed the consecutive medical records of 31 HCC patients with residual tumors located at complex sites (such as large blood vessels, gallbladder, diaphragm dome, etc.) after TACE from May 2014 to December 2018, all of whom received (125)I seeds implantation therapy. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were documented. RESULTS: A total of 607 seeds were implanted in 31 patients, with an average of 19.6±10.4 (range, 8–48) seeds per patient. Median OS and PFS were 33 months (95% CI: 27.1 months, 38.9 months) and 15 months (95% CI: 9.6 months, 20.4 months), respectively. Although univariate analysis showed that albumin, prothrombin time, alpha-fetoprotein level, Child-Pugh score, and lipiodol deposition in tumor were associated with OS, multivariate analysis showed that none of them was an independent prognostic factor for OS. Multivariate analysis showed that prothrombin time was an independent prognostic factor for PFS. No operation-related deaths in this study. Although pneumothorax was present in two patients and subcutaneous abscess in one patient, symptoms improved in all three patients with appropriate treatment. Common minor complications included fever, abdominal pain and leukopenia and no grade≥3 adverse events were observed. CONCLUSIONS: (125)I seeds implantation under the combined guidance of ultrasound and CT is safe and effective for patients with residual HCC located at complex sites after TACE. This is a promising treatment approach and deserves further discussion. |
format | Online Article Text |
id | pubmed-7961082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79610822021-03-17 Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization Ren, Yanqiao Dong, Xiangjun Chen, Lei Sun, Tao Alwalid, Osamah Kan, Xuefeng Su, Yangbo Xiong, Bin Liang, Huimin Zheng, Chuansheng Han, Ping Front Oncol Oncology PURPOSE: The purpose of this study was to evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolization (TACE). METHODS: This retrospective study analyzed the consecutive medical records of 31 HCC patients with residual tumors located at complex sites (such as large blood vessels, gallbladder, diaphragm dome, etc.) after TACE from May 2014 to December 2018, all of whom received (125)I seeds implantation therapy. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were documented. RESULTS: A total of 607 seeds were implanted in 31 patients, with an average of 19.6±10.4 (range, 8–48) seeds per patient. Median OS and PFS were 33 months (95% CI: 27.1 months, 38.9 months) and 15 months (95% CI: 9.6 months, 20.4 months), respectively. Although univariate analysis showed that albumin, prothrombin time, alpha-fetoprotein level, Child-Pugh score, and lipiodol deposition in tumor were associated with OS, multivariate analysis showed that none of them was an independent prognostic factor for OS. Multivariate analysis showed that prothrombin time was an independent prognostic factor for PFS. No operation-related deaths in this study. Although pneumothorax was present in two patients and subcutaneous abscess in one patient, symptoms improved in all three patients with appropriate treatment. Common minor complications included fever, abdominal pain and leukopenia and no grade≥3 adverse events were observed. CONCLUSIONS: (125)I seeds implantation under the combined guidance of ultrasound and CT is safe and effective for patients with residual HCC located at complex sites after TACE. This is a promising treatment approach and deserves further discussion. Frontiers Media S.A. 2021-03-02 /pmc/articles/PMC7961082/ /pubmed/33738247 http://dx.doi.org/10.3389/fonc.2021.582544 Text en Copyright © 2021 Ren, Dong, Chen, Sun, Alwalid, Kan, Su, Xiong, Liang, Zheng and Han http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ren, Yanqiao Dong, Xiangjun Chen, Lei Sun, Tao Alwalid, Osamah Kan, Xuefeng Su, Yangbo Xiong, Bin Liang, Huimin Zheng, Chuansheng Han, Ping Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization |
title | Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization |
title_full | Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization |
title_fullStr | Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization |
title_full_unstemmed | Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization |
title_short | Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization |
title_sort | combined ultrasound and ct-guided iodine-125 seeds implantation for treatment of residual hepatocellular carcinoma located at complex sites after transcatheter arterial chemoembolization |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961082/ https://www.ncbi.nlm.nih.gov/pubmed/33738247 http://dx.doi.org/10.3389/fonc.2021.582544 |
work_keys_str_mv | AT renyanqiao combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT dongxiangjun combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT chenlei combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT suntao combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT alwalidosamah combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT kanxuefeng combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT suyangbo combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT xiongbin combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT lianghuimin combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT zhengchuansheng combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization AT hanping combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization |